XNAS 20 Jul, 2026 11:42 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2026 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2026 | 1,080 | 1,080 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 2,875 | 125,750 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 1,779 | 115,092 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 30 Jun 2026 | 2,875 | 54,651 | - | 12.7 | 36,369 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 30 Jun 2026 | 1,779 | 56,430 | - | 8.0 | 14,303 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 30 Jun 2026 | 4,654 | 51,776 | - | 20 | 93,080 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 23 Jun 2026 | 1,450 | 53,226 | - | 8.0 | 11,658 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2026 | 1,450 | 116,871 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 23 Jun 2026 | 1,450 | 51,776 | - | 18 | 26,100 | Common Stock |
| Paul Varki | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 1,081 | 32,576 | - | 13.1 | 14,161 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 138 | 40,773 | - | 13.1 | 1,808 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 1,084 | 51,776 | - | 13.1 | 14,200 | Common Stock |
| Jennifer Riley | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 588 | 39,696 | - | 13.1 | 7,703 | Common Stock |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 29,500 | 29,500 | - | - | Stock Option (Right to Buy) | |
| Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Samantha Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2026 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2026 | 679 | 118,321 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 28 May 2026 | 679 | 47,122 | - | 16 | 10,864 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 28 May 2026 | 679 | 47,801 | - | 8.0 | 5,459 | Common Stock |
| Garry A. Neil | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 100,200 | 190,314 | - | 0 | Common Stock | |
| Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 24,300 | 27,934 | - | 0 | Common Stock | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 39,900 | 40,323 | - | 0 | Common Stock | |
| Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 43,500 | 47,122 | - | 0 | Common Stock | |
| Jennifer Riley | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 34,200 | 36,855 | - | 0 | Common Stock | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 15 May 2026 | 3,000 | 6,622 | - | 12.7 | 37,950 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2026 | 3,000 | 128,625 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.76 per share. | 15 May 2026 | 3,000 | 3,622 | - | 18.8 | 56,280 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. | 07 May 2026 | 18,606 | 19,029 | - | 9.9 | 183,827 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 18,606 | 168,094 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 07 May 2026 | 18,606 | 423 | - | 24.1 | 448,818 | Common Stock |
| Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.43 per share. | 06 May 2026 | 62,500 | 66,134 | - | 13.4 | 839,375 | Common Stock |
| Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 12,563 | 87,437 | - | - | Stock Option (Right to Buy) | |
| Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 62,500 | 87,500 | - | - | Stock Option (Right to Buy) | |
| Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 23.71 per share. | 06 May 2026 | 400 | 3,634 | - | 23.7 | 9,484 | Common Stock |
| Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 22.70 per share. | 06 May 2026 | 9,253 | 4,034 | - | 22.7 | 210,029 | Common Stock |
| Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.22 per share. | 06 May 2026 | 22,839 | 13,287 | - | 21.2 | 484,541 | Common Stock |
| Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 19.78 per share. | 06 May 2026 | 5,196 | 36,126 | - | 19.8 | 102,783 | Common Stock |
| Paul Varki | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 18.91 per share. | 06 May 2026 | 37,375 | 41,322 | - | 18.9 | 706,836 | Common Stock |
| Paul Varki | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 May 2026 | 12,563 | 78,697 | - | 8.0 | 101,007 | Common Stock |
| Mitchell Chan | Director | Sale of securities on an exchange or to another person at price $ 22.88 per share. | 06 May 2026 | 3,167 | 3,166 | - | 22.9 | 72,461 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.57 per share. | 06 May 2026 | 8,900 | 423 | - | 22.6 | 200,913 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.37 per share. | 06 May 2026 | 9,219 | 9,323 | - | 21.4 | 197,008 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 06 May 2026 | 2,700 | 18,542 | - | 20.8 | 56,052 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 47,000 | 116,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 06 May 2026 | 13,834 | 33,589 | - | 18.6 | 256,655 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 May 2026 | 47,000 | 47,423 | - | 8.0 | 377,880 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.28 per share. | 06 May 2026 | 12,347 | 21,242 | - | 19.3 | 238,093 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 May 2026 | 679 | 5,301 | - | 8.0 | 5,459 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 28,650 | 119,000 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 77,905 | 131,625 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 679 | 147,650 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2026 | 1,000 | 209,530 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.88 per share. | 05 May 2026 | 10,058 | 3,622 | - | 22.9 | 230,127 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.41 per share. | 05 May 2026 | 19,015 | 13,680 | - | 22.4 | 426,050 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.20 per share. | 05 May 2026 | 44,944 | 32,695 | - | 21.2 | 952,669 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.65 per share. | 05 May 2026 | 5,000 | 77,639 | - | 19.7 | 98,251 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 05 May 2026 | 27,538 | 82,639 | - | 18.0 | 496,405 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 May 2026 | 28,650 | 110,177 | - | 8.0 | 230,346 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 05 May 2026 | 77,905 | 81,527 | - | 12.6 | 985,498 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 05 May 2026 | 1,679 | 3,622 | - | 16 | 26,864 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 05 May 2026 | 1,000 | 4,622 | - | 12.7 | 12,650 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 29 Apr 2026 | 8,457 | 423 | - | 13.2 | 111,853 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.09 per share. | 29 Apr 2026 | 8,458 | 8,880 | - | 13.1 | 110,736 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 06 Apr 2026 | 3,970 | 7,592 | - | 12.7 | 50,221 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Apr 2026 | 3,970 | 210,530 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 06 Apr 2026 | 3,970 | 3,622 | - | 18.0 | 71,508 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 01 Apr 2026 | 7,479 | 25,318 | - | 16.8 | 125,841 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.57 per share. | 01 Apr 2026 | 1,780 | 17,338 | - | 17.6 | 31,270 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 01 Apr 2026 | 6,200 | 19,118 | - | 17.0 | 105,553 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.86 per share. | 01 Apr 2026 | 500 | 32,797 | - | 15.9 | 7,929 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 01 Apr 2026 | 679 | 3,622 | - | 16 | 10,864 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 679 | 148,329 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 01 Apr 2026 | 679 | 4,301 | - | 8.0 | 5,459 | Common Stock |
| Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 1,370 | 1,370 | - | - | Stock Option (Right to Buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2026 | 1,339 | 1,339 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 6,333 | - | - | Common Stock | |
| Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 3,167 | - | - | Restricted Stock Units | |
| Garry A. Neil | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 28 Mar 2026 | 21,892 | 90,114 | - | 13.9 | 304,080 | Common Stock |
| Garry A. Neil | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 64,866 | 112,006 | - | - | Common Stock | |
| Garry A. Neil | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 64,866 | 64,867 | - | - | Restricted Stock Units | |
| Mitchell Chan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 3,167 | - | - | Restricted Stock Units | |
| Mitchell Chan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 6,333 | - | - | Common Stock | |
| Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 28 Mar 2026 | 8,241 | 33,297 | - | 13.9 | 114,467 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 24,200 | 41,538 | - | - | Common Stock | |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 24,200 | 24,200 | - | - | Restricted Stock Units | |
| Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 3,167 | - | - | Restricted Stock Units | |
| Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 6,333 | - | - | Common Stock | |
| Samantha Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 6,333 | - | - | Common Stock | |
| Samantha Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 3,167 | - | - | Restricted Stock Units | |
| Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 3,167 | - | - | Restricted Stock Units | |
| Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 3,166 | 3,166 | - | - | Common Stock | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.65 per share. | 16 Mar 2026 | 19,500 | 23,122 | - | 12.7 | 246,675 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 5,992 | 149,008 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 19,500 | 214,500 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 16 Mar 2026 | 25,492 | 3,622 | - | 16.1 | 411,607 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 16 Mar 2026 | 5,992 | 29,114 | - | 8.0 | 48,176 | Common Stock |
| Garry A. Neil | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 286,000 | 286,000 | - | - | Stock Option (Right to Buy) | |
| Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Riley | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Taylor Boyd | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | |
| Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 848 | 848 | - | - | Stock Option (Right to Buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 1,043 | 1,043 | - | - | Stock Option (Right to Buy) | |
| Paul Varki | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 1,016 | 3,634 | - | 4.1 | 4,166 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 155 | 17,338 | - | 4.1 | 636 | Common Stock |
| Mittie Doyle | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 1,013 | 3,622 | - | 4.1 | 4,153 | Common Stock |
| Jennifer Riley | Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 637 | 2,655 | - | 4.1 | 2,612 | Common Stock |
| Jonathan Goldman | Director | Sale of securities on an exchange or to another person at price $ 14.30 per share. | 14 Nov 2025 | 3,167 | 0 | - | 14.3 | 45,288 | Common Stock |
| Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2025 | 8,200 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Jonathan Goldman | Director | Sale of securities on an exchange or to another person at price $ 14.35 per share. | 14 Nov 2025 | 8,200 | 0 | - | 14.3 | 117,649 | Common Stock |
| Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. | 14 Nov 2025 | 8,200 | 8,200 | - | 9.9 | 81,016 | Common Stock |
| Kevin R. Lind | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 40,200 | 40,200 | - | - | Stock Option (Right to Buy) | |
| Taylor Boyd | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2025 | 1,572 | 1,572 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 29,500 | 29,500 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Samantha Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Jonathan Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 40,200 | 40,200 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Gilla Kaplan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| June S. Almenoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| June S. Almenoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Garry A. Neil | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 64,867 | 129,733 | - | - | Restricted Stock Units | |
| Garry A. Neil | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 64,867 | 64,927 | - | - | Common Stock | |
| Garry A. Neil | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 17,787 | 47,140 | - | 8.5 | 150,478 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 48,400 | - | - | Restricted Stock Units | |
| Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 24,206 | - | - | Common Stock | |
| Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 7,285 | 16,921 | - | 8.5 | 61,631 | Common Stock |
| Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Samantha Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Samantha Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Mitchell Chan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Mitchell Chan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Jonathan Goldman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 411,000 | 411,000 | - | - | Stock Option (Right to Buy) | |
| Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 163,000 | 163,000 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer Riley | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 12 Nov 2024 | 500 | 500 | - | 12.5 | 6,250 | Common Stock | |
| June S. Almenoff | Director | 12 Nov 2024 | 500 | 1,000 | - | 13 | 6,500 | Common Stock | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 500,400 | 500,400 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 194,600 | 194,600 | - | - | Restricted Stock Units | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 186,700 | 186,700 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 72,600 | 72,600 | - | - | Restricted Stock Units | |
| June S. Almenoff | Director | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | ||
| June S. Almenoff | Director | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | ||
| Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Samantha Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Samantha Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Jonathan Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Jonathan Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 234,000 | 234,000 | - | - | Stock Option (Right to Buy) | |
| Paul Varki | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | |
| Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | |
| Almenoff S. June | Director | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2023 | 3,334 | 3,334 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 30 Jun 2023 | 4,575 | 4,575 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 28,308 | 28,308 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 4,000 | 13,220 | - | 3.4 | 13,680 | Common Stock |
| Christopher Ryan Sullivan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 511 | 1,262 | - | 3.4 | 1,748 | Common Stock |
| Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 31 Mar 2023 | 1,167 | 1,167 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 7,222 | 7,222 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 30 Dec 2022 | 410 | 410 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 2,536 | 2,536 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Director, CEO and Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 09 Dec 2022 | 2,083 | 9,220 | - | 4.4 | 9,207 | Common Stock |
| Garry A. Neil | Director, CEO and Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 3,080 | 3,080 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 30 Sep 2022 | 605 | 605 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 3,747 | 3,747 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 44,115 | 44,115 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 30 Jun 2022 | 4,338 | 4,338 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 26,837 | 26,837 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Mitchell Chan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 30,359 | 30,359 | - | - | Stock Option (Right to Buy) | |
| June S. Almenoff | Director | 31 Mar 2022 | 2,985 | 2,985 | - | - | Stock Option (Right to Buy) | ||
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 18,468 | 18,468 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 20,239 | 20,239 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 1,000,000 | 1,000,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 4,267 | 85,639 | - | 1.6 | 6,699 | Common Stock |
| James A. Harrell | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 1,093 | 36,766 | - | 1.6 | 1,716 | Common Stock |
| H. Jeffrey Wilkins | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 6,371 | 33,373 | - | 1.6 | 10,002 | Common Stock |
| Christopher Ryan Sullivan | Chief Accounting Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 955 | 9,004 | - | 1.6 | 1,499 | Common Stock |
| Schond L. Greenway | CFO | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 2,231 | 3,883 | - | 1.6 | 3,503 | Common Stock |
| June S. Almenoff | Director | 10 Nov 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | ||
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 78,116 | 78,116 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 9,541 | 9,541 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 5,204 | 5,204 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 4,718 | 4,718 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 5,985 | 5,985 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 6,939 | 6,939 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 51,740 | 51,740 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 6,353 | 6,353 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 3,465 | 3,465 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 3,142 | 3,142 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 3,985 | 3,985 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2021 | 4,620 | 4,620 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Sol J. Barer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Jun 2021 | 3,692 | 81,372 | - | 2.3 | 8,418 | Common Stock |
| James A. Harrell | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Jun 2021 | 7,493 | 35,673 | - | 2.3 | 17,084 | Common Stock |
| H. Jeffrey Wilkins | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Jun 2021 | 912 | 27,002 | - | 2.3 | 2,079 | Common Stock |
| Schond L. Greenway | CFO | Purchase of securities on an exchange or from another person at price $ 2.68 per share. | 10 Jun 2021 | 652 | 1,652 | - | 2.7 | 1,747 | Common Stock |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 70,881 | 70,881 | - | - | Stock Option (Right to Buy) | |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 7,650 | 7,650 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 4,173 | 4,173 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 3,783 | 3,783 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 4,799 | 4,799 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2021 | 5,564 | 5,564 | - | - | Stock Option (Right to Buy) | |
| Schond L. Greenway | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 850,000 | 850,000 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 260,000 | 260,000 | - | - | Stock Option (right to buy) | |
| James A. Harrell | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Ryan Sullivan | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 64,798 | 64,798 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Dec 2020 | 3,599 | 77,680 | - | 2.3 | 8,199 | Common Stock |
| James A. Harrell | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Dec 2020 | 171 | 28,180 | - | 2.3 | 390 | Common Stock |
| Christopher Ryan Sullivan | Interim CFO | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Dec 2020 | 5,095 | 8,049 | - | 2.3 | 11,606 | Common Stock |
| Gilla Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 76,674 | 76,674 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 4,325 | 4,325 | - | - | Stock Option (Right to Buy) | |
| Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 4,516 | 4,516 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 5,099 | 5,099 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 6,374 | 6,374 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 64,683 | 64,683 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 2,130 | 2,130 | - | - | Stock Option (Right to Buy) | |
| Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 3,812 | 3,812 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 4,304 | 4,304 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 4,005 | 4,005 | - | - | Stock Option (Right to Buy) | |
| Sol J. Barer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 1,000,000 | 1,000,000 | - | - | Stock Option (Right to Buy) | |
| Sol J. Barer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 84,322 | 84,322 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Garry A. Neil | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Jun 2020 | 1,799 | 74,081 | - | 2.3 | 4,098 | Common Stock |
| Christopher Ryan Sullivan | Interim CFO | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Jun 2020 | 2,954 | 2,954 | - | 2.3 | 6,729 | Common Stock |
| Michael F. Cola | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 09 Jun 2020 | 100,000 | 175,746 | - | 2.5 | 250,000 | Common Stock |
| James A. Harrell | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 09 Jun 2020 | 6,391 | 28,009 | - | 2.3 | 14,559 | Common Stock |
| James A. Harrell | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 09 Jun 2020 | 10,000 | 21,618 | - | 2.5 | 25,000 | Common Stock |
| Joseph M. Miller | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.22 per share. | 08 Jun 2020 | 4,472 | 40,582 | - | 3.2 | 14,400 | Common Stock |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Simon C. Pedder | Director, Executive Chairman of the Bd | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.57 per share. | 09 Apr 2020 | 20,901 | 241,833 | - | 2.6 | 53,716 | Common Stock |
| James A. Harrell | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2020 | 268,000 | 268,000 | - | - | Stock Option (Right to Buy) | |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 2,007 | 2,007 | - | - | Stock Option (Right to Buy) | |
| Philip Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 4,310 | 4,310 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2020 | 4,866 | 4,866 | - | - | Stock Option (Right to Buy) | |
| Sol J. Barer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 1,200,000 | 1,200,000 | - | - | Stock Option (Right to Buy) | |
| Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 75,746 | 75,746 | - | - | Common Stock | |
| Garry A. Neil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 72,282 | 72,282 | - | - | Common Stock | |
| Garry A. Neil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2019 | 11,016 | 1,106 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2019 | 2,375 | 2,375 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2019 | 2,682 | 2,682 | - | - | Stock Option (Right to Buy) | |
| James A. Harrell | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Dec 2019 | 3,064 | 11,618 | - | 2.8 | 8,725 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Dec 2019 | 2,598 | 48,777 | - | 2.8 | 7,398 | Common Stock |
| Pericles Calias | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Dec 2019 | 2,913 | 52,462 | - | 2.8 | 8,295 | Common Stock |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2019 | 1,819 | 1,819 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2019 | 3,907 | 3,907 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2019 | 4,411 | 4,411 | - | - | Stock Option (Right to Buy) | |
| Simon C. Pedder | Director, Executive Chairman of the Bd | Purchase of securities on an exchange or from another person at price $ 2.98 per share. | 27 Aug 2019 | 6,734 | 262,734 | - | 3.0 | 20,100 | Common Stock |
| Matthew V. Phillips | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 1.07 per share. | 23 Aug 2019 | 512,500 | 512,500 | - | 1.1 | 548,375 | Common Stock |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Keith W. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Pericles Calias | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.90 per share. | 16 Jul 2019 | 3,246 | 49,216 | - | 4.9 | 15,905 | Common Stock |
| Simon C. Pedder | Director, Executive Chairman of the Bd | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 117 | 117 | - | - | Stock Option (Right to Buy) | |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 1,172 | 1,172 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 2,323 | 2,323 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2019 | 2,636 | 2,636 | - | - | Stock Option (Right to Buy) | |
| Keith W. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2019 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Matthew V. Phillips | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Jun 2019 | 523 | 1,020 | - | 2.8 | 1,489 | Common Stock |
| James A. Harrell | Exec. VP, Mktg & External Comm | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Jun 2019 | 4,398 | 8,554 | - | 2.8 | 12,523 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Jun 2019 | 1,179 | 46,179 | - | 2.8 | 3,357 | Common Stock |
| Pericles Calias | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Jun 2019 | 4,549 | 49,549 | - | 2.8 | 12,953 | Common Stock |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2019 | 375,000 | 375,000 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 07 Jun 2019 | 3,723 | 45,054 | - | 4.9 | 18,057 | Common Stock |
| Simon C. Pedder | Director, Executive Chairman of the Bd | Purchase of securities on an exchange or from another person at price $ 5.06 per share. | 14 May 2019 | 6,000 | 6,000 | - | 5.1 | 30,336 | Common Stock |
| Simon C. Pedder | Director, Executive Chairman of Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2019 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Matthew V. Phillips | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| James A. Harrell | Exec. VP, Mktg & External Comm | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Pericles Calias | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2019 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Simon C. Pedder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 882 | 882 | - | - | Employee Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 1,916 | 1,916 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 2,286 | 2,286 | - | - | Employee Stock Option (Right to Buy) | |
| Simon C. Pedder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2018 | 1,504 | 1,504 | - | - | Stock Option (Right to Buy) | |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2018 | 3,095 | 3,095 | - | - | Stock Option (Right to Buy) | |
| Isaac Blech | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2018 | 8,519 | 8,519 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2018 | 3,439 | 3,439 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2018 | 4,103 | 4,103 | - | - | Stock Option (Right to Buy) | |
| Patrick J. Crutcher | VP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2018 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Patrick J. Crutcher | VP, Business Development | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Dec 2018 | 6,871 | 1,634,771 | - | - | Common Stock | |
| Matthew V. Phillips | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Dec 2018 | 497 | 497 | - | 2.8 | 1,415 | Common Stock |
| James A. Harrell | Exec. VP, Mktg & External Comm | Purchase of securities on an exchange or from another person at price $ 2.85 per share. | 10 Dec 2018 | 4,156 | 4,156 | - | 2.8 | 11,834 | Common Stock |
| Simon C. Pedder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2018 | 990 | 990 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2018 | 6,041 | 6,041 | - | - | Employee Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2018 | 2,351 | 2,351 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2018 | 2,696 | 2,696 | - | - | Employee Stock Option (Right to Buy) | |
| Patrick J. Crutcher | VP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Sep 2018 | 1,641,642 | 1,641,642 | - | 0 | Common Stock | |
| Randal O. Jones | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.98 per share. | 13 Aug 2018 | 1,270 | 0 | - | 4.0 | 5,055 | Common Stock |
| Randal O. Jones | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 13 Aug 2018 | 1,270 | 1,270 | - | 3.2 | 4,064 | Common Stock |
| Randal O. Jones | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2018 | 1,270 | 0 | - | - | Stock Option (Right to Buy) | |
| Pericles Calias | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2018 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2018 | 45,000 | 45,000 | - | 0 | Common Stock | |
| Simon C. Pedder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2018 | 1,012 | 1,012 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2018 | 6,881 | 6,881 | - | - | Employee Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2018 | 2,544 | 2,544 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2018 | 2,747 | 2,747 | - | - | Employee Stock Option (Right to Buy) | |
| Randal O. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2018 | 1,012 | 1,012 | - | - | Employee Stock Option (Right to Buy) | |
| Simon C. Pedder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 8,357 | 8,357 | - | - | Stock Option (Right to Buy) | |
| Uli Hacksell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 8,357 | 8,357 | - | - | Stock Option (Right to Buy) | |
| Isaac Blech | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 8,357 | 8,357 | - | - | Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 8,357 | 8,357 | - | - | Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2018 | 8,357 | 8,357 | - | - | Stock Option (Right to Buy) | |
| James A. Harrell | Exec. VP, Mktg & External Comm | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2018 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Simon C. Pedder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2018 | 16,714 | 16,714 | - | - | Stock Option (right to buy) | |
| Eugene A. Bauer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2018 | 2,262 | 2,262 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2018 | 6,111 | 6,111 | - | - | Employee Stock Option (Right to Buy) | |
| Philip P. Gutry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2018 | 2,350 | 2,350 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2018 | 2,791 | 2,791 | - | - | Employee Stock Option (Right to Buy) | |
| Randal O. Jones | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2018 | 2,056 | 2,056 | - | - | Employee Stock Option (Right to Buy) | |
| Mariam E. Morris | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2018 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
| Matthew V. Phillips | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2018 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2017 | 3,060 | 3,060 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2017 | 8,267 | 8,267 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2017 | 3,179 | 3,179 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2017 | 3,776 | 3,776 | - | - | Employee Stock Option (Right to Buy) | |
| Randal O. Jones | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2017 | 1,270 | 1,270 | - | - | Employee Stock Option (Right to Buy) | |
| Robert C. Moscato | Director, COO | Purchase of securities on an exchange or from another person at price $ 1.77 per share. | 04 Dec 2017 | 285 | 2,592,743 (0%) | 0% | 1.8 | 504 | Shares of common stock |
| Randal O. Jones | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2017 | 16,714 | 16,714 | - | - | Stock Option (right to buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2017 | 10,202 | 10,202 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2017 | 27,560 | 27,560 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2017 | 10,600 | 10,600 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2017 | 12,587 | 12,587 | - | - | Employee Stock Option (Right to Buy) | |
| John J. Kaiser | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2017 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 13,690 | 13,690 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 36,982 | 36,982 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 14,224 | 14,224 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2017 | 16,891 | 16,891 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 10,764 | 10,764 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 10,764 | 21,528 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 9,751 | 9,751 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 26,342 | 26,342 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 10,131 | 10,131 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2017 | 12,031 | 12,031 | - | - | Employee Stock Option (Right to Buy) | |
| Uli Hacksell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2017 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mariam E. Morris | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2017 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| John J. Kaiser | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2017 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2016 | 7,301 | 7,301 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2016 | 8,060 | 8,060 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2016 | 17,827 | 17,827 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2016 | 3,793 | 3,793 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2016 | 9,008 | 9,008 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2016 | 1,706 | 1,706 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2016 | 1,883 | 1,883 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2016 | 3,723 | 3,723 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2016 | 886 | 886 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2016 | 2,105 | 2,105 | - | - | Employee Stock Option (Right to Buy) | |
| Uli Hacksell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 130,000 | 130,000 | - | - | Employee Stock Option (Right to Buy) | |
| Mariam E. Morris | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 32,500 | 32,500 | - | - | Employee Stock Option (Right to Buy) | |
| John J. Kaiser | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 32,500 | 32,500 | - | - | Employee Stock Option (Right to Buy) | |
| Ronald Marcus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2016 | 40,000 | 40,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2016 | 3,153 | 3,153 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2016 | 3,481 | 3,481 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2016 | 6,881 | 6,881 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2016 | 1,638 | 1,638 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2016 | 3,891 | 3,891 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2016 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2016 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2016 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2016 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2016 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Behshad Sheldon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2016 | 8,357 | 8,357 | - | - | Employee Stock Option (Right to Buy) | |
| Mariam E. Morris | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2016 | 10,100 | 10,100 | - | - | Employee Stock Option (Right to Buy) | |
| John J. Kaiser | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2016 | 31,288 | 31,288 | - | - | Employee Stock Option (Right to Buy) | |
| Ronald Marcus | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2016 | 44,286 | 44,286 | - | - | Employee Stock Option (Right to Buy) | |
| Thomas H. Aasen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2016 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Uli Hacksell | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2016 | 360,459 | 388,780 | - | - | Employee Stock Option (Right to Buy) | |
| Eugene A. Bauer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2015 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Uli Hacksell | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2015 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2015 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Phil Gutry | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2015 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Magnus Persson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2015 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Behshad Sheldon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2015 | 16,714 | 16,714 | - | - | Employee Stock Option (Right to Buy) | |
| Anthony A. Florence | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Anthony A. Florence | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| David M. Mott | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| David M. Mott | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| M. James Barrett | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| M. James Barrett | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Forest Baskett | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Forest Baskett | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Krishna Kolluri | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Krishna Kolluri | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Peter J. Barris | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Peter J. Barris | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Harry R. Weller | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Harry R. Weller | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Patrick J. Kerins | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Patrick J. Kerins | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Sandell D Scott | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Sandell D Scott | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock | ||
| Ravi Viswanathan | Ten Percent Owner | 20 Oct 2015 | 16,638,880 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Ravi Viswanathan | Ten Percent Owner | 20 Oct 2015 | 594,245 | 594,245 | - | - | Common Stock |